Bavarian Nordic A/S bags US$120m for smallpox vaccine

Bavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government.       

Read more

Neuraxpharm pays US$650m for MS drug commercialisation

TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy.

Read more

PureTech Health gets US$11.4m to advance LYT-300

LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome.

Read more

NK cell therapy company NK:IO raises seed money

British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.

Read more

Alnylam in US$2.8bn biobucks deal with Roche

siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T

Read more

Resistance blocker of immune checkpoint inhibitors gets patented

The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.

Read more

Biomethane fuel offers negative carbon footprint

Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.

Read more